COMPANY NEWS

Myocardial Solutions Raises $7.0 Million in Series C Financing

By Myocardial Solutions

/

March 6, 2019

MORRISVILLE, N.C., March 6, 2019 – After its initial closing of $6.6 million in December, Myocardial Solutions, Inc. has rounded out and completed its’ Series C financing round of $7.0 million of equity investment. The funding round was led by a family office. The company has now raised a total of $16.0 million since it was founded in January 2016. The primary use of the funds will be to build out the company’s resources and infrastructure to commercialize its’ patented technology, MyoStrain®. MyoStrain, which quantifies asymptomatic cardiac dysfunction in a 10-minute MRI exam, has its CE Mark and FDA 510(k) clearance.

Kyle Peterson, the Director of Strategic Development for Myocardial Solutions, commented: “We completed our Series C financing which will allow the company to achieve several important milestones.  With our recent FDA 510(k) clearance, this round of financing will allow us to initiate the commercial launch of MyoStrain in both the United States and Europe. We are very grateful to our investors for their continued support in our goal to become the standard of care for cardiac function testing worldwide.”

Media Contact

Ahmed Osman
PR@myocardialsolutions.com
919.802.6411 

About Myocardial Solutions, Inc.

Myocardial Solutions, Inc. (MSI) is a medical technology company working to transform the cardiac and cancer care continuum. Leveraging more than 400 publications in clinical research and development, MSI’s proprietary technology, MyoStrain®, is a 10-minute, non-invasive heart function test providing physicians with sensitive diagnostic markers to support the early assessment and individualized treatment of heart dysfunction. MyoStrain has received FDA-510(k) pre-market clearance, CE-mark certification, and is commercially available in the United States and Europe.

To learn more about MyoStrain, visit myocardialsolutions.com or connect with us on LinkedIn and Twitter @myocardialsoln.